Quality Over Quantity: EMA's New Approach to Biosimilars
By Rob Coker
April 23, 2025
EMA reflection paper considers elimination of routine comparative efficacy studies for biosimilars.
2 min read
False
Advertisement
Biosimilars
AI Approach to Transdermal GLP-1s
February 25, 2025
How do you design, refine, and optimize novel GLP-1 drugs that could improve patient experiences? With a computer, of course.
3 min read
Celebrating the Potential of Biosimilars
By Josh Gissing
February 5, 2025
A look at how biosimilars can increase patient access to essential medicines, as well as improve performance in national and international healthcare systems.
3 min read
From Start-Up Biotech to the Boardroom
May 21, 2024
Sitting Down With… Anne Marie de Jonge-Schuermans, Board Member of the Swiss Biotech Association and Global Head of Biologics & Injectables Operations at Sandoz
5 min read
Enter the Humira Biosimilars
By Stephanie Vine
July 14, 2023
Humira biosimilars finally launch on the US market
2 min read
The Imperfect Art of Biosimilars
By Dave Li, Anna Baran
May 25, 2023
Need a refresher on biosimilars? Here, we offer some key points to keep in mind when it comes to structure, function, and interchangeability.
5 min read
Here Come the Humira Biosimilars
By Stephanie Vine
February 9, 2023
The first Humira biosimilar in the US is here, but market penetration could be a challenge
2 min read
Catching Up With the Biologics Sector: Download Our eBook
September 30, 2022
Our free eBook showcases content on bioprocess scale up, biosimilars, primary packaging considerations, and more
2 min read
Finding A Niche
By Dominic Marasco
August 25, 2022
How can companies carve out a position in a saturated biosimilars market?
2 min read
Quick-Fire Q&A: Biosimilars in the US
By Stephanie Vine
May 30, 2022
Biosimilars have been available in Europe for years. Is the US still lagging behind?
3 min read
